Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex(®) 10% Versus Gammaplex(®) 5% in Subjects with Primary Immunodeficiency

PURPOSE: This phase 3, multicenter, open-label, randomized, two-period, crossover bioequivalence trial evaluated the safety, tolerability, and pharmacokinetics of intravenous immunoglobulins (IVIGs) Gammaplex 5% and Gammaplex 10% in 33 adults and 15 children with primary immunodeficiency diseases (P...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Immunol
Autores principales: Wasserman, Richard L., Melamed, Isaac R., Stein, Mark R., Jolles, Stephen, Norton, Miranda, Moy, James N.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5487756/
https://ncbi.nlm.nih.gov/pubmed/28316003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-017-0383-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares